Dr. Cash is a Pediatric Hematologist/Oncologist at the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta and Assistant Professor of Pediatrics in the Division of Pediatric Hematology/Oncology. He received his Bachelor of Science degree in chemistry from Auburn University and subsequently obtained his medical degree from the University of Alabama School of Medicine in Birmingham, Ala. He completed his residency training at the University of Arkansas for Medical Sciences Pediatric Training Program at Arkansas Children’s Hospital, in Little Rock, Ark., before coming to Atlanta for his pediatric hematology/oncology fellowship at Emory University. Dr. Cash received additional research training through obtaining his Master of Science in clinical research (MSc) from Emory University. After completion of his fellowship, Dr. Cash completed a year as a senior associate at Emory, where he received mentored training in early-phase clinical trials and I-MIBG therapy. He then joined the faculty at Emory as Assistant Professor.
Dr. Cash’s clinical expertise is in pediatric solid tumors such as neuroblastoma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma and other soft tissue sarcomas. He is Medical Director for the Solid Tumor Program and is a member of the developmental therapeutics team at the Aflac Cancer and Blood Disorders Center. Dr. Cash also treats patients in the MIBG and Relapsed/Refractory Neuroblastoma Program. Additionally, he serves as institutional principal investigator for the Children’s Oncology Group (COG).
Dr. Cash's research objectives stem from his clinical focus in treating pediatric solid tumor patients with recurrent and/or refractory disease. His broad objective is to identify novel therapeutic agents and to bring the most promising of these agents to clinical trials to improve the outcomes for pediatric patients with relapsed or refractory disease. Dr. Cash is the study chair and co-investigator on many local and national trials, including the following:
- AflacST1502 (CHOAnome) Study chair
- AflacST1501 (Abemaciclib) Co-investigator
- AflacST1603 Study co-chair
- AflacST1402 Study co-chair
- COG ADVL1515 Study vice-chair
- NANT 2017-01 Study chair
Focus of Practice
- Relapsed and or refractory solid tumors
Areas of Interest
- MIBG therapy
- Developmental therapeutics